Show simple item record

AuthorMartini, Maurizio
Authorde Pascalis, Ivana
AuthorD'Alessandris, Quintino Giorgio
AuthorFiorentino, Vincenzo
AuthorPierconti, Francesco
AuthorMarei, Hany El-Sayed
AuthorRicci-Vitiani, Lucia
AuthorPallini, Roberto
AuthorLarocca, Luigi Maria
Available date2018-07-02T06:13:38Z
Publication Date2018-05-10
Publication NameBMC Canceren_US
Identifierhttp://dx.doi.org/10.1186/s12885-018-4442-2
CitationMartini, M., Pascalis, I. D., D’Alessandris, Q. G., Fiorentino, V., Pierconti, F., Marei, H. E., . . . Larocca, L. M. (2018). VEGF-121 plasma level as biomarker for response to anti-angiogenetic therapy in recurrent glioblastoma. BMC Cancer, 18(1). doi:10.1186/s12885-018-4442-2
ISSN1471-2407
URIhttp://hdl.handle.net/10576/6778
AbstractVascular endothelial growth factor (VEGF) isoforms, particularly the diffusible VEGF-121, could play a major role in the response of recurrent glioblastoma (GB) to anti-angiogenetic treatment with bevacizumab. We hypothesized that circulating VEGF-121 may reduce the amount of bevacizumab available to target the heavier isoforms of VEGF, which are the most clinically relevant. We assessed the plasma level of VEGF-121 in a brain xenograft model, in human healthy controls, and in patients suffering from recurrent GB before and after bevacizumab treatment. Data were matched with patients' clinical outcome. In athymic rats with U87MG brain xenografts, the level of plasma VEGF-121 relates with tumor volume and it significantly decreases after iv infusion of bevacizumab. Patients with recurrent GB show higher plasma VEGF-121 than healthy controls (p = 0.0002) and treatment with bevacizumab remarkably reduced the expression of VEGF-121 in plasma of these patients (p = 0.0002). Higher plasma level of VEGF-121 was significantly associated to worse PFS and OS (p = 0.0295 and p = 0.0246, respectively). Quantitative analysis of VEGF-121 isoform in the plasma of patients with recurrent GB could be a promising predictor of response to anti-angiogenetic treatment.
Languageen
PublisherBioMed Central
SubjectAntiangiogenetic-therapy
SubjectRecurrent glioblastoma
SubjectTarget therapy
SubjectVEGF isoforms
TitleVEGF-121 plasma level as biomarker for response to anti-angiogenetic therapy in recurrent glioblastoma.
TypeArticle
Pagination1-7
Issue Number1
Volume Number18


Files in this item

Icon

This item appears in the following Collection(s)

Show simple item record